PMID- 18094414
OWN - NLM
STAT- MEDLINE
DCOM- 20080304
LR  - 20231213
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 13
IP  - 24
DP  - 2007 Dec 15
TI  - HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs 
      Specific for Malignant Glioma.
PG  - 7329-34
AB  - PURPOSE: The interleukin-13 receptor alpha 2 (IL-13R alpha 2) is a 
      glioma-restricted cell-surface epitope not otherwise detected within the central 
      nervous system. Here, we report a novel approach for targeting malignant glioma 
      with IL-13R alpha 2-specific CTLs. EXPERIMENTAL DESIGN: Artificial 
      antigen-presenting cells (aAPC) were made by coating human leukocyte antigen 
      (HLA)-A2/pIL-13R alpha 2(345-354) tetrameric complexes, anti-CD28 antibody, and 
      CD83 molecules to cell-sized latex beads, and used to stimulate IL-13R alpha 
      2-specific CTLs from the peripheral blood mononuclear cells of HLA-A2+ healthy 
      donors. After multiple stimulations, the induced CTLs were analyzed for tetramer 
      staining, IFN-gamma production, and CTL reactivity. RESULTS: Tetramer staining 
      assay showed that the induced CTLs specifically bound HLA-A2/pIL-13R alpha 
      2(345-354) tetramers. The CTLs specifically produced IFN-gamma in response to the 
      HLA-A2/pIL-13R alpha 2(345-354)-aAPCs and exhibited specific lysis against T2 
      cells pulsed with the peptide pIL-13R alpha 2(345-354) and HLA-A2+ glioma cells 
      expressing IL-13R alpha 2(345-354), whereas HLA-A2(-) glioma cell lines that 
      express IL-13R alpha 2(345-354) could not be recognized by the CTLs. The 
      peptide-specific activity was inhibited by anti-HLA class I monoclonal antibody. 
      CONCLUSION: The induced CTLs specific for IL-13R alpha 2(345-354) peptide could 
      be a potential target of specific immunotherapy for HLA-A2+ patients with 
      malignant glioma.
FAU - Jiang, Xiaobing
AU  - Jiang X
AD  - Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China. jxb917@126.com
FAU - Lu, Xiaoling
AU  - Lu X
FAU - Liu, Ruen
AU  - Liu R
FAU - Zhang, Fangcheng
AU  - Zhang F
FAU - Zhao, Hongyang
AU  - Zhao H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens, CD)
RN  - 0 (CD28 Antigens)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukin-13 Receptor alpha2 Subunit)
RN  - 0 (Membrane Glycoproteins)
SB  - IM
MH  - Antigen-Presenting Cells/*immunology
MH  - Antigens, CD/immunology
MH  - Brain Neoplasms/*immunology
MH  - CD28 Antigens/immunology
MH  - Cells, Cultured
MH  - Coculture Techniques
MH  - Gene Expression
MH  - Glioma/*immunology
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Immunoglobulins/immunology
MH  - Interleukin-13 Receptor alpha2 Subunit/immunology
MH  - Lymphocyte Activation/immunology
MH  - Membrane Glycoproteins/immunology
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - CD83 Antigen
EDAT- 2007/12/21 09:00
MHDA- 2008/03/05 09:00
CRDT- 2007/12/21 09:00
PHST- 2007/12/21 09:00 [pubmed]
PHST- 2008/03/05 09:00 [medline]
PHST- 2007/12/21 09:00 [entrez]
AID - 13/24/7329 [pii]
AID - 10.1158/1078-0432.CCR-07-1025 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2007 Dec 15;13(24):7329-34. doi: 10.1158/1078-0432.CCR-07-1025.